Table 1.
Cancer type | Clinicopathological features | References |
---|---|---|
Hepatocellular carcinoma | Poor prognosis, liver cirrhosis microvascular invasion, macrovascular invasion encapsulation, PVTT tissues | Yuan et al., 2014 |
Gastric cancer | Poor prognosis, TNM stage vascular invasion, lymph node metastasis | Saito et al., 2015; Lei et al., 2017 |
Colorectal cancer | Tumor size, lymphatic invasion, poor prognosis vascular invasion, lymph node metastasis | Iguchi et al., 2015; Yue et al., 2016 |
Breast cancer | Trastuzumab resistance HER2-positive breast cancers | Shi et al., 2015 |
Prostate cancer | Poor prognosis, histological grade, biochemical recurrence preoperative PSA level, pathological stage, gleason score, lymph node metastasis, angiolymphatic invasion | Xu et al., 2016 |
Renal cell carcinoma | Tumor stages, histological grade, vascular invasion, lymph node metastasis, distant metastasis | Xiong et al., 2016 |
Non-small cell lung cancer | TNM stages, lymph node metastasis, distant metastasis tumor size, poor prognosis | Ke et al., 2017 |
Glioma | Tumor grades, tumor size, poor prognosis | Ma et al., 2016 |
Osteosarcoma | Poor prognosis, enneking stage metastasis, recurrence | Han et al., 2017 |
Pancreatic cancer | Lymphatic metastasis, neural invasion, prognosis neural invasion | Qu et al., 2016 |
PVTT, Portal vein tumor thrombus; TNM, tumor node metastasis; HER2, human epidermal growth factor receptor 2; PSA, Prostate Specific Antigen.